Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04367311
Title Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors >= 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Nasser Hanna
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Cisplatin + Pemetrexed Disodium

Atezolizumab + Cisplatin + Docetaxel

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Northwestern University Feinberg School of Medicine Recruiting Chicago Illinois 60611 United States Details
Indiana University Melvin and Bren Simon Cancer Center Recruiting Indianapolis Indiana 46202 United States Details
Rutgers Cancer Institute of New Jersey Recruiting New Brunswick New Jersey 08903 United States Details
New York University Clinical Cancer Center Recruiting New York New York 10016 United States Details
Penn State Cancer Institute Recruiting Hershey Pennsylvania 17033 United States Details
University of Wisconsin Recruiting Madison Wisconsin 53705 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field